Lack of guidelines creates high rates of missed Lynch syndrome diagnosis in UTUC
“We found that while the NCCN guideline for Lynch syndrome is highly specific in identifying patients with Lynch syndrome, it missed about 50% of patients with upper tract cancer who had Lynch syndrome,” says Hong Truong, MD.
In this video, Hong Truong, MD,discusses the findings of the study, “Defining hereditary upper tract urothelial carcinoma: Implications for genetic testing and clinical management,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Truong is a urologic oncology fellow at Memorial Sloan Kettering Cancer Center in New York, New York.
Study links PARP inhibitors to increased risk of hematologic toxicity in mCRPC patients
November 23rd 2023A recently published study found an association between PARP inhibitor treatment and an increased risk of hematological adverse events, including anemia, thrombocytopenia, and neutropenia, in patients with metastatic castration-resistant prostate cancer.
Mistrust of medical research may discourage genetic testing in prostate cancer
November 20th 2023According to the survey, 79% of Black men know that genetic information can help improve prostate cancer outcomes, yet 33% indicated that they would be unwilling or uncertain to provide DNA samples, even if it meant finding new treatment options.
